Francisco Fernandez-Aviles Diaz is Professor of Cardiovascular Medicine at the Complutense University and Chairman of the Department of Cardiology in the Hospital Gregorio Marañón of Madrid. He is also the Scientific Director of the Spanish Network Centre for Cardiovascular Research (CIBERCV, Instituto de Salud Carlos III, Spanish Ministry of Science).
He participates in various national and international public and private organizations as an expert on the planning and the assessment of medical care, teaching and research activity. He belongs to the Editorial Board of the main cardiovascular journals and is Fellow of the American College of Cardiology and the European Society of Cardiology, for which he has served as Councillor and Vice-President.
Prof. Fernández-Avilés is Chairman of the Working Group on CV Regeneration and Repair of the European Society of Cardiology and leads the Transnational Alliance for Regenerative Therapies in Cardiovascular Syndromes (TACTICS). He also leads one most productive groups of Spanish Medicine. In addition, as Scientific Director of the CIBERCV, he coordinates the best basic and clinical cardiovascular research groups of Spain (www.cibercv.es). Together with his institutional and organizational responsibilities, he combines an intense clinical and academic activity. His research focuses on the protection and regeneration of the damaged myocardium. He has worked on this field using different approaches including preclinical and clinical models of myocardial injury to test different drugs, medical devices and different types of stem cells. He has received multiple awards and has published more than 700 articles abstracts and book chapters, with a total impact factor of 1703.02, a cumulative citation index of 13727 and a H index of 42.
Cell Therapy Program Coordinator
Full professor of Cell Biology, Department of Surgical, Medical Odontoiatry and Morphological Sciences, University of Modena e Reggio Emilia, Modena, Italy
Cell Therapy Program Coordinator, Centre for Regenerative Medicine "Stefano Ferrari", University of Modena e Reggio Emilia, Modena, Italy
R&D Director, Holostem Terapie Avanzate S.r.l., Modena, Italy
Johannes Boltze, M.D., Ph.D., heads the Department of Cell Therapy at Fraunhofer Institute for Cell Therapy and Immunology in Leipzig. The Department of Cell Therapy comprises six research groups: Immunotherapy and Oncology, Ischemia Research Unit, Experimental Imaging, Stem Cell Biology, Cognitive Genetics and Clinic-oriented Therapy Assessment. Dr. Boltze also directs two research groups at the University of Leipzig. His research interests are the development of novel diagnostic or therapeutic approaches for ischemic diseases, particularly stroke, and experimental neurosurgery. He is currently a visiting professor at the Neuroscience Center of the Massachusetts General Hospital, Harvard University.
Universidad de los Andes, Chile
Master and PhD in Gene Therapy, University of Montpellier, France, and postdoctoral work at the Koch Institute of Massachusetts Institute of Technology (MIT), USA. He led a Cell Therapy project at the Singapore-MIT Alliance (SMART) labs in Singapore. He currently serves as Scientific Director (CSO) of Cells for Cells, spin-off of Universidad de los Andes, Chile.
Lead Systems Designer/Project Manager for Cell & Gene Therapy, GE Healthcare Life Sciences.
Trevor is a technical lead and project manager on the Cell & Gene Therapy team at GE Healthcare Life Sciences. Trevor works closely with both the R&D teams and product management to facilitate the verification, validation, and launching of innovative new products. His recent focus has been the expansion of the media and reagents portfolio but has also included the iterative development of consumable products such as disposable bioreactors.
Prior to GE Healthcare, Trevor has worked for the Department of Defense as a research microbiologist investigating in vitro test methodologies for evaluating antimicrobial textiles to improve soldier health and hygiene.
Trevor received his MS in Microbiology from Seton Hall University where he completed his laboratory thesis on vaccine development using dendritic cells. He is currently pursuing an MBA in Health Sector Management at Boston University.